Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic.
TypeArticle; Peer-Reviewed Publication
Journal TitleFrontline Gastroenterology
MetadataShow full item record
AbstractThe risk of patients with IBD acquiring SARS-CoV-2 and developing COVID-19 will depend on their inherent personal risk factors and modifiable factors such as active IBD and immunosuppression. Fortunately, we will be able to refine the risk profile for each individual patient iteratively as more data become available.45 46 We recommend that effective treatment for IBD should not be postponed idefinately until patients have received the COVID-19 vaccine Three SARS-CoV-2 vaccines have been approved and the BSG and other organisations are in favour of patients with IBD to accept the first vaccine offered.47 48 Healthcare services and patients have rapidly adjusted to new working practices stimulated by the COVID-19 pandemic. Our next challenge is to truly transform our services using data-driven clinical decision-making, proactively monitoring disease and supporting patient engagement as the pandemic evolves.
CitationDin S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol. 2021 Apr 21;13(1):77-81. doi: 10.1136/flgastro-2021-101805. PMID: 34966535; PMCID: PMC8666864.
Publisher Linkhttps://fg.bmj.com/content/13/1/77; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666864/
RightsAttribution-NonCommercial 3.0 United States
The following license files are associated with this item: